Parkinson's disease is a neurodegenerative disorder that have an effect on predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Symptoms normally develop slowly over years. The development of symptoms is often different from one person to another due to the diversity of the disease. People with Parkinson’ may experience: Tremor, mainly at rest and described as pill rolling tremor in hands. Other forms of tremor are possible Bradykinesia, Limb rigidity, Gait and balance problems.
The Parkinson’s disease treatment market is estimated to reach $5.69 Billion by 2022 from $4.24 Billion in 2017, at a CAGR of 6.1%. The market is being operated by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government investment for research. Globally, Parkinson’s disease treatment market is segmented into North America, Europe, Asia. In addition, Europe is forecasted to hold the largest share of the market in 2017, Asia is expected to grow at the highest CAGR.
Neuroscientists, Researchers, Professors, Neurosurgeons, Psychiatrist, Lecturers and Students from Academia in the study of Parkinson disease, Students from Academia in the research of Neurology and Neuroscience
Parkinson disease, causes, symptoms, Parkinson pathophysiology, Epidemiology of Parkinson’s disease, Neurocognitive and Neuromuscular Disorders, Risk Factors of Parkinsons disease, Diagnostic and Neuroimaging for Parkinsons Disease, Managing life with Parkinsons disease, Novel therapeutics for Parkinsons disease, Clinical Trials in Parkinsons disease, Deep brain stimulation
68 Quai de la Seine, 75019 Paris, France